Financial results: Elixinol; Emyria; Epsilon; Avecho; Creso Pharma; AusCann; MGC Pharma; Botanix; Zelira by Martin Lane and Steve Jones March 1, 2023April 30, 2024 Elixinol Wellness reported a 2022 year-end loss of A$10.5m, a 38% improvement on the previous year, […]
Cann Group to focus on ‘production at scale’ as new CEO beds down by Steve Jones February 28, 2023April 30, 2024
Montu rejects ‘hijack’ claim as row erupts over awareness week website by Steve Jones February 23, 2023April 30, 2024
Vitura Health relishes competition as firm begins ‘phase two’ of growth plan by Steve Jones February 16, 2023April 30, 2024
Elixinol wins A$835k arbitration ruling in stoush with German operator by Steve Jones February 14, 2023April 30, 2024
Vitura Health reports record half as CanView continues to thrive by Martin Lane February 13, 2023February 13, 2023
Shelf-life claims on TGA radar as industry warned of widespread consequences by Steve Jones February 9, 2023February 9, 2023
Legalise Cannabis Victoria introduces drug-driving bill to parliament by Martin Lane February 8, 2023March 1, 2023
Asterion’s Australian vision in tatters as firm goes into liquidation by Steve Jones February 8, 2023February 8, 2023
Queensland firm ditches cultivation plans as money runs dry by Steve Jones February 8, 2023February 8, 2023
